Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (IV) insulin infusion.
Specific Aims: To evaluate the impact of early administration of subcutaneous glargine versus standard care on time of insulin infusion in DKA patients and other secondary outcomes listed in this application.
Methods: DKA patients enrolled in this study will receive the long acting glargine dose (0.3 units/kg with a maximum dose of 30 units) within two hours after initiation the IV insulin infusion. Besides timing of the glargine dose, no other changes in standard patient care will occur in those patients enrolled in this study, the same labs will be collected and the insulin infusion will be titrated using the same hospital protocol algorithm.
Patients enrolled in the prospective arm will be compared with the retrospective control group, which received standard insulin therapy (subcutaneous insulin glargine administered at least 2 to 3 hours prior to termination of the insulin infusion). There will be 18 patients in this group selected in reverse chronological order from our pre-specified date range of 8/1/2014 to 7/31/2016.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early glargine dose | Experimental | Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion. |
|
| Standard therapy | Placebo Comparator | Retrospective arm that received standard insulin therapy for treatment of DKA |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Early administration of subcutaneous insulin glargine dose | Other | DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units. |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of intravenous insulin infusion | Measured in minutes from starting insulin infusion | up to 10 months |
| Measure | Description | Time Frame |
|---|---|---|
| Time to resolution of high serum glucose (hyperglycemia) | Measured in minutes from starting insulin infusion | up to 10 months |
| Time to closure of anion gap | Measured in minutes from starting insulin infusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| George C Willis, MD | Director of Undergraduate Medical Education | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Maryland Medical Center | Baltimore | Maryland | 21217 | United States |
Individual subject results will not be shared with those involved in the prospective arm.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016883 | Diabetic Ketoacidosis |
| D004630 | Emergencies |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D007662 | Ketosis |
| D000138 | Acidosis |
| D000137 | Acid-Base Imbalance |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| IV insulin infusion | Other | All patients will receive the standard of care which is a protocol based continuous insulin infusion |
|
| IV fluid repletion | Drug | 0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL. |
|
| up to 10 months |
| Time to correction of bicarbonate | Measured by serum bicarbonate | up to 10 months |
| Time to correction of serum pH | Measured by pH on venous blood gas | up to 10 months |
| Total duration of hospital stay | Measured in days | up to 10 months |
| Return of DKA within 24 hours | Indicated by presence of diagnostic criteria within 24 hours of starting insulin infusion | up to 10 months |
| Incidence of low serum glucose (hypoglycemia) within 24 hours | Measure by serum glucose. | up to 10 months |
| D009750 |
| Nutritional and Metabolic Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |